Program
14:00 – 14:10
WELCOME ADDRESS
14:10 – 16:00
SESSION 1: REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES
KEYNOTE LECTURE
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
RWE: BEYOND CRS AND ICANS: HEMATOTOXICITY AND INFECTIONS AS DRIVERS OF CAR-T NRM
Marion Subklewe, LETSimmun Consortium, Germany
Jennifer Brogdon, Novartis, USA
Panel discussion
16:00 – 16:40
COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS & POSTER VIEWING
16:40 – 18:00
SESSION 2: SUPERPOWERED LYMPHOCYTES
A PRIVATE CROSSTALK ESTABLISHED BY TUMOR-TARGETED CYTOKINE RELEASE RESCUES CAR-T ACTIVITY AND ENGAGES HOST T CELLS AGAINST GLIOBLASTOMA
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
ENGINEERING T-CELLS FOR SUPERIOR PERFORMANCE
George Coukos, Ludwig Cancer Research Lausanne Branch, Switzerland
OVERCOMING T CELL SENESCENCE BY GENOME EDITING
Chiara Bonini, Vita-Salute San Raffaele University, Italy
TBC
Panel discussion
18:00 – 19:30
MEET THE POSTER PRESENTERS & WELCOME RECEPTION
09:00 – 10:10
SESSION 3: NON-VIRAL CAR/TCR GENE TARGETING
He Huang, Zhejiang University School of Medicine, China
CAR-TS GOING NON-VIRAL FROM BENCH TO BEDSIDE (AND BACK)
Michael Hudecek, LETSimmun Consortium, Germany
TBC
Panel Discussion
10:10 – 10:50
COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS & POSTER VIEWING
10:50 – 12:20
SESSION 4: CUTTING-EDGE INDUSTRY ADVANCEMENTS
12:20 – 13:50
LUNCH BREAK, TOP 10 POSTER PRESENTATIONS, EXHIBITION & POSTER VIEWING
13:50 – 15:15
SESSION 5: CAR/TCR MRNA THERAPIES
KEYNOTE LECTURE
Drew Weissman, University of Pennsylvania School of Medicine, USA
MRNA-BASED T CELL ENGINEERING FOR VIRUS-RELATED CANCERS (HBV-HCC) AND VIRAL INFECTIONS
Antonio Bartoletti, A*STAR, Singapore
TBC
Panel Discussion
15:15 – 15:25
SHORT BREAK
15:25 – 16:35
SESSION 6: UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING
TARGETING CANCER WITH T-CELL RECEPTOR-ENGINEERED T CELLS
Johanna Olweus, Oslo University, Norway
Dirk Busch, Technical University of Munich, Germany
TBC
Panel Discussion
16:35 – 17:30
ENGAGE & ENERGIZE: NETWORKING AND INSPIRATIONAL BREAK
17:30 – 19:10
SESSION 7: UPDATED CLINICAL DATA
KEYNOTE LECTURE
Carl June, University of Pennsylvania, USA
TBC
Panel discussion
08:30 – 09:30
SESSION 8: BEYOND ALPHA-BETA CELLS
FROM AUTOLOGOUS TO ALLOGENEIC CAR EFFECTOR CELLS: PUSHING THE BOUNDARIES FROM CANCER TO OTHER SEVERE DISEASES
Ulrike Kohl, Fraunhofer Institute for Cell Therapy and Immunology Leipzig, Germany
TBC
Panel discussion
09:30 – 11:05
SESSION 9: TARGETING NON-MALIGNANT DISEASES
CAR T CELL TREATMENT IN AUTOIMMUNE DISEASE
George Schett, Friedrich-Alexander University of Erlangan-Nuremberg, Germany
Adi Barzel, Tel Aviv University, Israel
MODIFICATION OF TCR/CD3 TO ENHANCE T CELL FUNCTION
Hans Stauss, University College London, UK
TBC
Panel discussion
11:05 – 11:40
COFFEE BREAK, EXHIBITION & POSTER PRESENTATIONS
11:40 – 12:40
SESSION 10: SELECTED ABSTRACTS FOR ORAL PRESENTATION
12:40 – 13:40
SESSION 11: IN VIVO AND BEDSIDE T CELL ENGINEERING
T-CELL TARGETED VECTORS FOR IN VIVO CAR DELIVERY
Christian Buchholz, PEI, Germany
EXTRACORPOREAL CAR GENE DELIVERY
David Peritt, Lupagen, USA
TBC
Panel Discussion
13:40 – 14:00
BEST POSTER ANNOUNCEMENT & CONFERENCE CLOSURE
Moderators: Adi Barzel, Tel-Aviv University, Israel
Dirk Busch, Technical University of Munich, Germany
